Dermata Therapeutics Inc. (DRMA)
NASDAQ: DRMA
· Real-Time Price · USD
4.90
-0.01 (-0.20%)
At close: Oct 03, 2025, 3:53 PM
4.84
-1.22%
After-hours: Oct 03, 2025, 07:10 PM EDT
-0.20% (1D)
| Bid | 4.8 |
| Market Cap | 3.34M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -10.33M |
| EPS (ttm) | 20.72 |
| PE Ratio (ttm) | 0.24 |
| Forward PE | -0.82 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 5.04 |
| Volume | 28,371 |
| Avg. Volume (20D) | 38,264 |
| Open | 4.98 |
| Previous Close | 4.91 |
| Day's Range | 4.81 - 5.03 |
| 52-Week Range | 4.55 - 23.70 |
| Beta | 0.56 |
| Ex-Dividend Date | n/a |
About DRMA
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol DRMA
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for DRMA stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts6 months ago
+5.19%
Dermata shares are trading higher after the compan...
Unlock content with
Pro Subscription
10 months ago
+19.01%
Dermata Therapeutics shares are trading higher after the company received a notice of allowance for a U.S. patent titled "COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN CONDITIONS (INCLUDING ACNE)"
3 weeks ago · accessnewswire.com
Dermata Therapeutics Announces Strategic Pivot to Over-the-Counter Skin Care TreatmentsSAN DIEGO, CA / ACCESS Newswire / September 10, 2025 / Dermata Therapeutics, Inc. (Nasdaq:DRMA)(Nasdaq:DRMAW) ("Dermata" or the "Company"), a science-driven leader in dermatologic solutions, today ann...
